HTL0014242

DRUG2 trials

Sponsors

Nxera Pharma UK Limited

Conditions

Healthy

Phase 1

Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242

CompletedNCT03785054

Nxera Pharma UK LimitedHealthy

Start: 2018-11-14End: 2021-03-11Updated: 2021-04-29

Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects

CompletedNCT04462263

Nxera Pharma UK LimitedHealthy

Start: 2020-06-29End: 2021-06-23Updated: 2021-07-07